# Tafenoquine in Patients With Mild to Moderate COVID-19

> **NCT04533347** · PHASE2 · COMPLETED · sponsor: **60 Degrees Pharmaceuticals LLC** · enrollment: 86 (actual)

## Conditions studied

- COVID 19 Disease

## Interventions

- **DRUG:** Tafenoquine Oral Tablet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04533347
- **Lead sponsor:** 60 Degrees Pharmaceuticals LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-19
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2025-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04533347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04533347, "Tafenoquine in Patients With Mild to Moderate COVID-19". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04533347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*